Shijiazhuang Longze Pharmaceutical

Shijiazhuang Longze Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the research, development, and manufacturing of anti-viral therapies, particularly for HIV/AIDS, Hepatitis B, and COVID-19. The company is a vertically integrated producer of high-quality Active Pharmaceutical Ingredients (APIs) and finished dosage forms, maintaining rigorous international quality standards with certifications from the US FDA, WHO, and EMA. Longze plays a critical role in global health as a key partner of the Medicines Patent Pool (MPP), facilitating the production of affordable generic versions of essential medications like dolutegravir and nirmatrelvir for developing nations. In addition to its internal product line, the company offers specialized CDMO services, leveraging its expertise in complex chemical synthesis and large-scale production. Headquartered in Shijiazhuang, Longze continues to expand its global footprint through strategic partnerships and a robust pipeline of anti-infective agents.